Investors Watch List: Stratasys Ltd. (NASDAQ:SSYS), Dun & Bradstreet Corp. (NYSE:DNB), Mead Johnson Nutrition Company (NYSE:MJN), Monogram Residential Trust, Inc. (NYSE:MORE),

Stratasys Ltd. (NASDAQ:SSYS) reported Revenue for the fourth quarter of 2015 was $173.4 million. GAAP net loss for the fourth quarter was $232.3 million, or ($4.46) per diluted share, compared to a loss of $92.0 million, or ($1.81).

Stratasys Ltd. (NASDAQ:SSYS) belongs to Technology sector. Its weekly performance is 46.63%. On last trading day company shares ended up at $27.64.

On 2 March, it was reported Dun & Bradstreet (NYSE:DNB) was recognized for providing the “Best Analytics for Credit Scoring and Supplier Risk Assessment” by Global Finance Magazine.

Dun & Bradstreet Corp. (NYSE:DNB) shares fell -0.26% in last trading session and ended the day at $100.90. DNB Gross Margin is 66.20% and its return on assets is 9.00%. Dun & Bradstreet Corp. (NYSE:DNB) quarterly performance is -4.46%.

Mead Johnson Nutrition Company (NYSE:MJN) announced that its board of directors has declared a regular quarterly dividend of $0.4125 per share for the quarter ending March 31, 2016. The dividend will be paid on April 1, 2016, to shareholders of record at close of business on March 14, 2016.

On 04 March, Mead Johnson Nutrition Company (NYSE:MJN) shares advanced 2.09% and was closed at $77.24. MJN EPS growth in last 5 year was 8.20%. Mead Johnson Nutrition Company (NYSE:MJN) year to date (YTD) performance is -2.17%.

Monogram Residential Trust (NYSE: MORE) declared a quarterly dividend of $0.075 per share, or $0.3 annualized. The dividend will be payable on April 7, 2016, to stockholders of record on March 31, 2016, with an ex-dividend date of March 29, 2016.

Monogram Residential Trust, Inc. (NYSE:MORE) ended the last trading day at $9.94. Company weekly volatility is calculated as 2.94% and price to cash ratio as 21.07. Monogram Residential Trust, Inc. (NYSE:MORE) showed a weekly performance of 8.87%.

AbbVie (NYSE: ABBV) announced the U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukemia (CLL).1 The approval is based on data from the randomized, multi-center, open-label Phase 3 RESONATE-2 (PCYC-1115) trial, which evaluated the use of IMBRUVICA versus chlorambucil in 269 treatment-naïve patients with CLL or small lymphocytic lymphoma (SLL) aged 65 years or older.

AbbVie Inc. (NYSE:ABBV) shares advanced 0.39% in last trading session and ended the day at $56.15. ABBV Gross Margin is 80.70% and its return on assets is 10.90%. AbbVie Inc. (NYSE:ABBV) quarterly performance is -1.70%.

Leave a Reply

Your email address will not be published. Required fields are marked *